Boehringer Ingelheim Acquires Northern Biologics’ Preclinical Cancer Antibody Pipeline, Expanding Immuno-oncology Portfolio

Boehringer Ingelheim acquired Northern Biologics Inc. in May 2020, gaining its preclinical pipeline of cancer antibodies. Northern Biologics focused on therapeutic antibodies targeting the tumour microenvironment. It is a sister company of Metrix Partners client Mosaic Biomedicals.

Boehringer Ingelheim acquisition of Northern Biologics pipeline

The deal

Boehringer Ingelheim bought Northern Biologics Inc., a wholly owned subsidiary of Northern LP. The acquisition positioned Boehringer Ingelheim in stromal biology, an emerging area of cancer immunology that studies the non-cancerous cells and structures around a tumour. The seller kept the Northern Biologics name and continued some preclinical work on one programme, while Boehringer Ingelheim took responsibility for clinical, regulatory and commercial development of the acquired programmes.

According to the announcement, it was the second recent transaction for a company built by Versant Ventures in the MaRS Discovery District in Toronto.

What stayed outside the deal

The lead clinical asset, MSC-1, an anti-LIF antibody that originated at Mosaic Biomedicals in Barcelona, was not part of the Boehringer Ingelheim transaction. Later in 2020, an AstraZeneca subsidiary acquired MSC-1. Splitting the portfolio between two buyers allowed each asset to go to the company best placed to develop it.

Why big pharma buys preclinical pipelines

Large pharmaceutical companies need a steady flow of new drug candidates. Buying preclinical programmes in emerging areas gives them early access to new biology at a lower price than clinical assets. Structures that leave some activities with the seller help close deals quickly and keep scientific teams engaged.

Five lessons from the Northern Biologics deal

  1. Emerging science attracts buyers. Stromal biology was a new area. Being early made Northern’s pipeline strategic.
  2. Carve-outs need clean structures. Separating the clinical asset from the preclinical pipeline required clear corporate and IP structures.
  3. Venture creation models work. Versant’s model of building companies around science and selling to pharma produced two exits in a short time.
  4. Retained rights matter. Keeping the name and some programmes let the seller pursue value from remaining assets.
  5. Deal structures vary. Upfront payments, milestones and retained activities should be modelled to understand the real value.

What biotech founders should prepare

  • Programme-level budgets and cost tracking.
  • Clear IP ownership and licences for each asset.
  • A corporate structure that allows assets to be sold separately.
  • Accounts reconciled to the statutory filings.
  • A data room organised by programme.

The Barcelona connection

The merger of Northern Biologics with Mosaic Biomedicals in 2016 linked a Toronto biotech with a Barcelona spin-off. The combination gave Mosaic’s science access to Versant’s capital and drug development experience, and gave Northern a clinical-stage candidate. The later deals with Boehringer Ingelheim and AstraZeneca show how cross-border structures can create value for founders and investors on both sides.

Metrix Partners in life sciences

Metrix has worked with Mosaic Biomedicals since its early stage and supports life sciences clients such as Ona Therapeutics, Accure Therapeutics and DeepUll.